UNICA IRIS Institutional Research Information System

MARONGIU, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 115.444
NA - Nord America 8.309
AS - Asia 1.009
OC - Oceania 49
SA - Sud America 36
AF - Africa 35
Continente sconosciuto - Info sul continente non disponibili 2
Totale 124.884
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 113.222
US - Stati Uniti d'America 8.209
UA - Ucraina 661
CN - Cina 655
SE - Svezia 552
GB - Regno Unito 250
DE - Germania 242
FI - Finlandia 213
CA - Canada 75
VN - Vietnam 64
SG - Singapore 60
FR - Francia 54
AU - Australia 41
IN - India 40
IE - Irlanda 33
RU - Federazione Russa 31
IR - Iran 30
NL - Olanda 28
ES - Italia 27
BE - Belgio 21
JP - Giappone 21
TR - Turchia 21
HK - Hong Kong 17
MX - Messico 16
KR - Corea 14
TW - Taiwan 13
BR - Brasile 12
EG - Egitto 11
IQ - Iraq 11
AT - Austria 10
ID - Indonesia 10
MY - Malesia 10
AL - Albania 9
RO - Romania 9
RS - Serbia 9
TH - Thailandia 9
CL - Cile 8
LT - Lituania 8
NZ - Nuova Zelanda 8
PH - Filippine 8
SD - Sudan 8
HU - Ungheria 7
PL - Polonia 7
BA - Bosnia-Erzegovina 6
BG - Bulgaria 6
CH - Svizzera 6
DK - Danimarca 6
PE - Perù 6
PK - Pakistan 6
ZA - Sudafrica 6
CO - Colombia 5
CZ - Repubblica Ceca 5
GR - Grecia 5
IL - Israele 4
MT - Malta 4
AE - Emirati Arabi Uniti 3
CR - Costa Rica 3
ET - Etiopia 3
PA - Panama 3
SK - Slovacchia (Repubblica Slovacca) 3
EE - Estonia 2
EU - Europa 2
GY - Guiana 2
HR - Croazia 2
KW - Kuwait 2
KZ - Kazakistan 2
MA - Marocco 2
MK - Macedonia 2
NO - Norvegia 2
PY - Paraguay 2
AM - Armenia 1
AN - Antille olandesi 1
AR - Argentina 1
BD - Bangladesh 1
CU - Cuba 1
CY - Cipro 1
DZ - Algeria 1
GE - Georgia 1
GT - Guatemala 1
IS - Islanda 1
KE - Kenya 1
LB - Libano 1
MO - Macao, regione amministrativa speciale della Cina 1
MZ - Mozambico 1
NG - Nigeria 1
NP - Nepal 1
OM - Oman 1
PT - Portogallo 1
SA - Arabia Saudita 1
TN - Tunisia 1
Totale 124.884
Salva come PNG Salva come JPEG
Città #
Cagliari 112.616
Fairfield 1.364
Woodbridge 838
Houston 646
Chandler 644
Ashburn 608
Seattle 549
Wilmington 524
Ann Arbor 463
Cambridge 449
Nyköping 442
Jacksonville 348
Dearborn 158
Boardman 153
Nanjing 111
Beijing 109
Boston 103
Helsinki 99
San Diego 85
Shanghai 71
Dong Ket 56
Hebei 55
New York 53
Milan 50
Shenyang 48
Redwood City 46
Toronto 41
Nanchang 36
Changsha 35
London 31
Guangzhou 30
Jiaxing 29
Los Angeles 24
Rome 24
Verona 24
Orange 23
Millbury 22
Brussels 21
Dublin 21
Norwalk 20
Sassari 19
Tianjin 19
Jinan 17
Mountain View 17
Redmond 16
Ningbo 15
Atlanta 14
Sydney 13
Auburn Hills 12
Central 12
Hefei 12
Quartu Sant'elena 11
Saint Petersburg 11
Frankfurt am Main 10
Saarbrücken 10
Ankara 9
Perth 9
Taizhou 9
Zhengzhou 9
Acate 8
Augusta 8
Hounslow 8
Stockholm 8
Taipei 8
Tirana 8
Washington 8
Chicago 7
Mumbai 7
Torino 7
Turin 7
Bangkok 6
Limerick 6
San Sperate 6
Santiago 6
Sofia 6
Tokyo 6
Vienna 6
Baghdad 5
Bucharest 5
Budapest 5
Cairo 5
Cleveland 5
Delhi 5
Edinburgh 5
Elmas 5
Hangzhou 5
Hanoi 5
Istanbul 5
Jakarta 5
Kilburn 5
Klaipėda 5
Kunming 5
Lahore 5
Munich 5
Nuoro 5
Phoenix 5
Acton 4
Alghero 4
Amsterdam 4
Andover 4
Totale 121.550
Salva come PNG Salva come JPEG
Nome #
The venous thromboembolic risk and the clot wave analysis: a useful relationship? 2.468
Prophylaxis of peripartum haemorrhage using recombinant factor VIIa (rfVIIa) in pregnant women with congenital factor VII deficiency: A case report and literature review 2.430
Heterogeneity of Antiphospholipid Syndrome (APS) as Characterized by Brain Perfusion Techniques. Towards New Ways of Syndrome Characterization 2.348
Acquired factor VIII inhibitor and subsequent development of non-Hodgkin's lymphoma: a case report and review of the literature 2.289
Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment. 2.240
Are prothrombin time and clot waveform analysis useful in detecting a bleeding risk in liver cirrhosis? 2.218
Olanzapine-associated portal and superior mesenteric vein thrombosis 2.149
Clot wave analysis and thromboembolic score in liver cirrhosis: two opposing phenomena 2.074
Pulmonary Thrombosis: A Clinical Pathological Entity Distinct from Pulmonary Embolism? 1.889
A retrospective cohort study of patients with pulmonary embolism: The impact of comorbidities on patient's outcome 1.886
A Sardinian Family with Factor XI Deficiency 1.791
Underuse of anticoagulant therapy in hospitalized older patients: comment on the article of Wojszel et al 1.773
Management of Patients Taking Oral Anticoagulants Who Need Urgent Surgery for Hip Fracture 1.734
A “Catastrophic” Heparin-Induced Thrombocytopenia 1.579
Points of Care Testing International Normalized Ratio: Are They Useful for Monitoring Vitamin K Antagonists in a Thrombosis Center? 1.543
Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience 1.538
Point-of-care testing INR: an overview 1.505
Vaping effects on asthma: results from a web survey and clinical investigation 1.484
Epidemiology of infection with HIV-1 in Sardinia: a multicentre prospective study 1.476
Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? No 1.454
Risk of reoperation in bioprosthetic valve patients with indication for longterm anticoagulation. Results from the observational retrospective multicentre PLECTRUM study 1.449
Comparison of prothrombin time INR and clot waveform analysis performed with 129-mmol/L and 105-mmol/L citrate tubes 1.406
Fibrinogen and D-dimer levels in autoimmune subclinical and overt hypothyroidism and effects of levothyroxine treatment. 1.401
Direct oral anticoagulants: what can we learn? 1.383
Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study 1.380
The hemostatic system. 1st Part 1.336
Pulmonary thrombosis in 2019-nCoV pneumonia? 1.333
T lymphocyte subsets and viral infections in Sardinian parenteral drug abusers: relationship to HIV infection 1.302
Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review 1.282
Optimizing tailored DIEP flap insetting in unilateral immediate free autologous breast reconstruction 1.274
Fatal Cytopenia Induced by Low-Dose Methotrexate in Elderly With Rheumatoid Arthritis. Identification of Risk Factors 1.253
Immunological aspects in anti-HIV seronegative drug addicts. Correlation with the duration of heroin addiction and other viral infections 1.248
Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules in patients on oral anticoagulants 1.228
The criteria of the Italian Federation of Thrombosis Centres on DOACs: a ‘‘real world’’ application in nonvalvular atrial fibrillation patients already on Vitamin K Antagonist 1.192
Allele 4G of gene PAI-I associated with prothrombin mutation G20210A increases the risk for venous thrombosis 1.157
Direct inhibitors of thrombin and factor Xa: the importance of laboratory skills 1.137
Telemedicine can improve the quality of oral anticoagulation using portable devices and self-testing at home 1.132
Uneven hepatic iron and phosphorus distribution in b-thalassemia 1.129
Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA(2)DS(2)VASc 1 or 2): a treatment dilemma 1.121
[Immunological aspects in anti-HIV seronegative drug addicts. Correlation with the duration of heroin addiction and other viral infections]. FT Aspetti immunologici nei tossicodipendenti anti-HIV sieronegativi. Correlazione con la durata di assunzione dell'eroina e con altre infezioni virali. 1.111
Antiphospholipid syndrome patients: The performance of Coagucheck XS in the monitoring of Vitamin K-Antagonists 1.056
The predictive ability of bleeding risk stratification models in very old patients on vitaminK antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study 1.054
Hyperhomocysteinemia: could the post-methionine oral loading test sometimes be avoided? 1.050
Vaccine-induced severe thrombotic thrombocytopenia following COVID-19 vaccination: A report of an autoptic case and review of the literature 1.026
Thyroid disorders and hypocoagulability 991
A ‘‘two-step’’ educational approach for patients taking oral anticoagulants does not improve therapy control 961
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome 960
Vitamin K antagonists (coumarins), drugs used in the prevention and treatment of cardioembolism, deep vein thrombosis, and pulmonary embolism 956
Aspetti immunologici nei tossicodipendenti anti-HIV sieronegativi. Correlazione con la durata di assunzione dell’eroina e con altre infezioni virali 947
A routine silica-based activated partial thromboplastin time (Hemosil aPTT-SP (TM)) mostly excludes the presence of lupus anticoagulant 929
Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago 922
High frequency of inadequate test requests for antiphospholipid antibodies in daily clinical practice 897
Sampling variability in hepatic iron concentration in beta-thalassemia 896
The Italian START-Register on anticoagulation with focus on atrial fibrillation 896
Plasma prekallikrein (Fletcher factor) in hepatic cirrhosis 884
Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA) 883
[Short-term effect of treatment with oral DL-carnitine and intravenous L-carnitine in chronic uremia patients undergoing hemodialytic therapy]. FT Effetto a breve termine della terapia con DL-carnitina per os ed L-carnitina e.v. nei pazienti uremici cronici in trattamento emodialitico. 881
Empathy and the Educational Approach to Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants 858
Short-term effect of treatment with oral DL-carnitine and intravenous L-carnitine in chronic uremia patients undergoing hemodialytic therapy 849
Thrombosis centres and AVKs monitoring in COVID-19 pandemic 840
null 824
Point-of-care (POCT) prothrombin time monitors: is a periodical control of their performance useful? 822
Hemarthrosis as acute presentation of acquired hemophilia in a patient with systemic lupus erythematosus: successful treatment and long-lasting remission 818
Center-related determinants of VKA anticoagulation quality: A prospective, multicenter evaluation 809
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a reply to a rebuttal 809
Rheumatoid arthritis and thrombosis 776
null 772
Thromboembolic disease in patients with rheumatoid arthritis undergoing joint arthroplasty: Update on prophylaxes 730
Start-register (Survey on anticoagulated patients register): the first year of activity 715
A guide to oral anticoagulation 712
Heparins and 2019-nCoV infection: a narrative review 701
Amoxicillina-acido clavulanico ed anticoagulanti orali:un’associazione potenzialmente pericolosa 689
Fondaparinux: Should It Be Studied in Patients with COVID-19 Disease? 680
null 679
Clot characterization by multidisciplinary approach: biochemical and imaging parameters in a hypocoagulative setting. A pilot study 668
Management of special conditions in patients on vitamin K antagonists 650
Bleeding diathesis and gastro-duodenal ulcers in inherited cytosolic phospholipase-A2 alpha deficiency 650
null 644
null 633
null 617
null 616
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 615
Special indications for vitamin K antagonists: a review 596
null 579
null 573
Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation 563
Fetal programming of COVID-19: May the barker hypothesis explain the susceptibility of a subset of young adults to develop severe disease? 558
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results 553
null 547
Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA) 531
Clinical history and gastrointestinal bleeding in patients taking oral anticoagulants 509
Superior sagittal sinus thrombosis after lumbar puncture in a patient with T-cell lymphoblastic lymphoma: role of the prothrombin G20210A mutation and 4G/4G genotype 499
Fetal programming of atherosclerosis: may the barker hypothesis explain the susceptibility of a subset of patients to develop stroke or cardiac infarct? 493
A pilot survey on chronic oral anticoagulation 492
null 491
Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2(V617F) mutation 489
Chronic intravascular coagulation in liver cirrhosis predicts a high hemorrhagic risk 481
Infectious agents including COVID-19 and the involvement of blood coagulation and fibrinolysis. A narrative review 479
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study 478
alpha 2 Antiplasmin and disseminated intravascular coagulation in liver cirrhosis 452
Totale 106.850
Salva come PNG Salva come JPEG
Categoria #
all - tutte 163.074
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 163.074
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.362 0 0 0 0 0 0 0 0 0 369 462 531
2019/202025.682 1.517 701 168 563 8.989 6.797 3.406 893 619 565 508 956
2020/202139.138 1.092 1.528 1.505 9.267 7.991 4.631 3.783 2.511 817 2.136 1.868 2.009
2021/20229.067 879 677 410 654 750 715 606 496 695 941 1.137 1.107
2022/202314.042 1.313 1.842 1.695 1.232 1.226 1.485 702 1.126 916 802 1.060 643
2023/202412.939 682 942 784 1.406 1.631 2.226 2.459 1.101 781 927 0 0
Totale 125.350